Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: UBXN2A (ImmuneEditome ID:165324)

1. Gene summary of enriched editing regions for UBXN2A

Gene summary

Gene information	Gene symbol	UBXN2A
	Gene ID	165324
	GeneSynonyms	UBXD4
	GeneCytomap	2p23.3
	GeneType	protein-coding
	GeneDescription	UBX domain-containing protein 2A\|UBX domain containing 4\|UBX domain-containing protein 4
	GeneModificationdate	20230528
	UniprotID	P68543
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr2:23928024-23928511:+	ENST00000446425.2	ENSG00000173960.11	UBXN2A	ncRNA_intronic	(GAAA)n,AluSz,AluSx1	chr2:23928024-23928511:+.alignment
chr2:23929576-23930982:+	ENST00000446425.2	ENSG00000173960.11	UBXN2A	ncRNA_intronic	FLAM_A,AluJo,AluSg7,AluSx1,AluSc8	chr2:23929576-23930982:+.alignment
chr2:23974780-23974977:+	ENST00000446425.2	ENSG00000173960.11	UBXN2A	ncRNA_intronic	AluSz	chr2:23974780-23974977:+.alignment
chr2:23974780-23974977:+	ENST00000479859.1	ENSG00000173960.11	UBXN2A	ncRNA_intronic	AluSz	chr2:23974780-23974977:+.alignment
chr2:23995529-23996297:+	ENST00000446425.2	ENSG00000173960.11	UBXN2A	ncRNA_intronic	AluY,AluSx3,AluSx,Tigger5b	chr2:23995529-23996297:+.alignment
chr2:24000317-24002742:+	ENST00000446425.2	ENSG00000173960.11	UBXN2A	ncRNA_exonic	AluSp,Charlie1b,AluJb,AluJr,AluSc,AluSx,AluSq2	chr2:24000317-24002742:+.alignment
chr2:24004352-24004635:+	ENST00000309033.4	ENSG00000173960.11	UBXN2A	UTR3	AluSc	chr2:24004352-24004635:+.alignment

Top

2. Tumor-specific enriched editing regions for UBXN2A

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr2:24000317-24002742:+	BRCA	EER	2.5415e-12
ENSG00000173960.11,UBXN2A	BRCA	EAG	9.8315e-06
ENSG00000173960.11,UBXN2A	KICH	EAG	1.3114e-02
chr2:24000317-24002742:+	LUSC	EER	1.4699e-02
ENSG00000173960.11,UBXN2A	THCA	EAG	3.9575e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr2:24004352-24004635:+	BLCA	Path	EER	1.6055e-02	8.1155e-03	-0.2061
chr2:24004352-24004635:+	KIRP	Path	EER	1.1796e-03	8.0897e-03	0.3036
chr2:24000317-24002742:+	LIHC	Path	EER	2.3140e-02	1.6706e-02	0.1902

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr2:24000317-24002742:+	STAD	EER	9.7524e-03	1.3072e-02	1.2366e+01

Top

3. Enriched editing regions and immune related genes for UBXN2A

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for UBXN2A

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr2:24000317-24002742:+

ESCA

EER

ENSG00000140740.6

chr16

21976166:21976243:21978882:21979082

-0.2972

2.8475e-02

1.5307e-06

-0.4014

CELF2;CSTF2T;DKC1;EIF4A3;ELAVL1;EWSR1;HNRNPK;HNRNPL;IGF2BP2;KHDRBS3;MSI2;NOP58;TARDBP;U2AF2;UPF1;NOP56

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

chr2:24000317-24002742:+

ESCA

EER

ENSG00000108826.11

chr17

50367864:50368313:50370031:50370099

-0.2903

2.4875e-02

8.9550e-07

-0.4485

CELF2;CSTF2T;EIF4A3;ELAVL1;HNRNPK;HNRNPL;IGF2BP2;MSI2;NOP58;TARDBP;U2AF2;UPF1;NOP56

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_GLYCOLYSIS

chr2:24000317-24002742:+

ESCA

EER

ENSG00000159216.14

chr21

34787800:34792610:34793544:34793648

-0.2280

4.9022e-02

9.0678e-06

-0.4024

CELF2;CSTF2T;DKC1;EIF4A3;ELAVL1;EWSR1;HNRNPK;HNRNPL;IGF2BP2;KHDRBS3;MSI2;NOP58;TARDBP;U2AF2;UPF1;NOP56

RUNX1

T_cells_gamma_delta

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

ENSG00000173960.11,UBXN2A

STAD

EAG

ENSG00000157456.3

chr15

59107321:59107450:59107565:59107670

-0.0633

1.5105e-02

4.6585e-18

-0.5096

ACIN1;ADAR;AIFM1;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

CCNB2

Macrophages_M1

chr2:24000317-24002742:+

STAD

EER

ENSG00000157456.3

chr15

59107321:59107450:59107565:59107670

-0.0685

8.7957e-03

7.5108e-13

-0.4471

CELF2;CSTF2T;DKC1;EIF4A3;ELAVL1;EWSR1;HNRNPK;HNRNPL;IGF2BP2;KHDRBS3;MSI2;NOP58;TARDBP;U2AF2;UPF1;NOP56

CCNB2

Macrophages_M1

ENSG00000173960.11,UBXN2A

TGCT

EAG

ENSG00000072840.8

chr4

5812588:5814162:5818210:5818254:5816086:5818254

-0.2718

1.4300e-02

4.4600e-05

-0.4040

ACIN1;ADAR;AIFM1;BCCIP;BUD13;CNBP;CSTF2T;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1

Macrophages_M2

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000173960.11,UBXN2A

TGCT

EAG

ENSG00000122783.12

chr7

135167731:135167807:135168968:135169060:135168748:135169060

0.3488

2.3372e-02

1.4641e-05

0.4004

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184

Macrophages_M2

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000173960.11,UBXN2A

TGCT

EAG

ENSG00000164877.14

chr7

1438096:1440085:1440590:1440684

0.4311

9.8748e-04

4.1164e-07

0.4684

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL1;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

MICALL2

B_cells_naive

GSVA_HALLMARK_HYPOXIA

ENSG00000173960.11,UBXN2A

TGCT

EAG

ENSG00000089157.11

chr12

120198553:120198631:120198853:120199000:120199117:120199205

-0.2725

6.4255e-03

3.4969e-06

-0.4259

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL1;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V2

ENSG00000173960.11,UBXN2A

TGCT

EAG

ENSG00000184831.9

chrX

23840312:23840373:23833359:23833510:23833359:23833612

-0.4114

3.7718e-03

4.7662e-06

-0.4188

ADAR;BUD13;CAPRIN1;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LARP4B;LIN28A;LIN28B;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SLTM;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1

Macrophages_M2

GSVA_HALLMARK_MYOGENESIS

More results

Top

5. Enriched editing regions and immune infiltration for UBXN2A

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000173960.11,UBXN2A	ACC	EAG	T_cells_CD8	2.2236e-04	0.5401
chr2:24000317-24002742:+	BLCA	EER	Eosinophils	3.4132e-02	-0.1360
chr2:24000317-24002742:+	BRCA	EER	T_cells_CD8	3.3700e-02	-0.0728
ENSG00000173960.11,UBXN2A	BRCA	EAG	T_cells_CD8	1.2519e-03	-0.1026
chr2:24000317-24002742:+	CESC	EER	Mast_cells_resting	1.0611e-02	-0.1764
ENSG00000173960.11,UBXN2A	CESC	EAG	T_cells_CD4_memory_resting	4.8678e-02	0.1258
chr2:24000317-24002742:+	COAD	EER	Mast_cells_activated	1.0257e-02	-0.1947
ENSG00000173960.11,UBXN2A	COAD	EAG	Dendritic_cells_activated	3.7029e-02	0.1476
chr2:24000317-24002742:+	ESCA	EER	Macrophages_M0	2.4994e-03	0.2435
ENSG00000173960.11,UBXN2A	ESCA	EAG	Macrophages_M0	2.7094e-03	0.2370
chr2:24000317-24002742:+	GBM	EER	Macrophages_M0	5.5340e-03	-0.2367
chr2:24000317-24002742:+	HNSC	EER	T_cells_gamma_delta	4.1248e-03	0.1484
ENSG00000173960.11,UBXN2A	HNSC	EAG	Mast_cells_activated	7.0391e-03	0.1332
chr2:24000317-24002742:+	KIRC	EER	Monocytes	1.4263e-02	0.1504
ENSG00000173960.11,UBXN2A	KIRC	EAG	Monocytes	4.3234e-03	0.1569
chr2:24004352-24004635:+	KIRP	EER	NK_cells_resting	2.1087e-07	0.5389
ENSG00000173960.11,UBXN2A	KIRP	EAG	NK_cells_resting	4.8694e-02	0.1476
ENSG00000173960.11,UBXN2A	LAML	EAG	Monocytes	3.7517e-02	0.2407
chr2:24000317-24002742:+	LIHC	EER	Macrophages_M0	1.9761e-02	0.1786
chr2:24000317-24002742:+	LUAD	EER	Macrophages_M1	9.1589e-03	-0.1541
ENSG00000173960.11,UBXN2A	LUAD	EAG	T_cells_CD4_memory_resting	7.0291e-03	0.1401
chr2:24000317-24002742:+	LUSC	EER	T_cells_follicular_helper	1.4960e-02	0.1323
ENSG00000173960.11,UBXN2A	LUSC	EAG	Mast_cells_resting	4.2152e-02	0.1012
chr2:24000317-24002742:+	MESO	EER	Macrophages_M1	7.5228e-03	0.3632
chr2:24004352-24004635:+	MESO	EER	T_cells_CD8	2.8557e-03	0.4256
ENSG00000173960.11,UBXN2A	MESO	EAG	B_cells_naive	1.2569e-02	-0.2990
chr2:23928024-23928511:+	OV	EER	T_cells_gamma_delta	7.1655e-04	0.5447
chr2:24000317-24002742:+	OV	EER	B_cells_memory	1.5889e-02	-0.1572
ENSG00000173960.11,UBXN2A	OV	EAG	T_cells_CD4_memory_activated	1.9942e-02	0.1411
chr2:24000317-24002742:+	PCPG	EER	Neutrophils	7.2959e-03	0.2736
ENSG00000173960.11,UBXN2A	PCPG	EAG	Macrophages_M1	1.2990e-02	-0.2208
chr2:24000317-24002742:+	PRAD	EER	NK_cells_resting	2.5304e-02	0.1262
ENSG00000173960.11,UBXN2A	PRAD	EAG	T_cells_CD4_memory_resting	8.8743e-03	0.1334
ENSG00000173960.11,UBXN2A	READ	EAG	B_cells_naive	2.4240e-02	0.2860
chr2:24000317-24002742:+	SARC	EER	B_cells_memory	1.2087e-02	-0.1867
ENSG00000173960.11,UBXN2A	SARC	EAG	T_cells_regulatory_(Tregs)	1.3381e-02	-0.1685
chr2:24000317-24002742:+	SKCM	EER	Macrophages_M0	1.0600e-03	-0.1705
ENSG00000173960.11,UBXN2A	SKCM	EAG	Dendritic_cells_resting	2.7348e-03	0.1491
chr2:23928024-23928511:+	STAD	EER	Plasma_cells	1.4653e-02	0.4822
chr2:24000317-24002742:+	STAD	EER	T_cells_CD4_memory_resting	4.0025e-03	0.1633
ENSG00000173960.11,UBXN2A	STAD	EAG	Neutrophils	1.1515e-02	-0.1379
chr2:24000317-24002742:+	TGCT	EER	Macrophages_M2	1.4703e-02	-0.2593
ENSG00000173960.11,UBXN2A	TGCT	EAG	B_cells_naive	4.7601e-02	0.1885
ENSG00000173960.11,UBXN2A	THCA	EAG	NK_cells_resting	1.2984e-02	-0.1221
chr2:24000317-24002742:+	THYM	EER	T_cells_CD8	1.4456e-02	0.3044
chr2:24004352-24004635:+	THYM	EER	Dendritic_cells_resting	2.9544e-02	-0.3247
chr2:24000317-24002742:+	UCEC	EER	Macrophages_M1	1.8875e-02	-0.2620
ENSG00000173960.11,UBXN2A	UCEC	EAG	Plasma_cells	1.0454e-02	0.2390
chr2:24004352-24004635:+	UCS	EER	T_cells_CD8	3.7445e-02	0.4183
ENSG00000173960.11,UBXN2A	UVM	EAG	NK_cells_activated	4.4927e-03	-0.4454

Top

6. Enriched editing regions and immune gene sets for UBXN2A

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr2:24000317-24002742:+	LUSC	EER	2.5462e-02		8.6904e-03	-0.1425

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr2:24000317-24002742:+	ESCA	EER	1.2772e-02	0.2016	2.1962e-02	0.1857	3.3108e-02	0.1730	1.6212e-02	0.1947

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000173960.11,UBXN2A	ACC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.0845e-02	0.3336
ENSG00000173960.11,UBXN2A	BLCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.5024e-04	0.2056
chr2:24004352-24004635:+	BLCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.9168e-02	0.1699
chr2:24000317-24002742:+	BLCA	GSVA_HALLMARK_GLYCOLYSIS	EER	4.4377e-03	0.1819
ENSG00000173960.11,UBXN2A	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.1312e-07	0.1643
chr2:24000317-24002742:+	BRCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.6439e-06	0.1563
ENSG00000173960.11,UBXN2A	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.2726e-06	0.2857
ENSG00000173960.11,UBXN2A	CHOL	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.6472e-02	-0.4587
chr2:24000317-24002742:+	COAD	GSVA_HALLMARK_GLYCOLYSIS	EER	4.2337e-03	-0.2164
ENSG00000173960.11,UBXN2A	COAD	GSVA_HALLMARK_GLYCOLYSIS	EAG	2.9058e-03	-0.2095
ENSG00000173960.11,UBXN2A	ESCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.0535e-03	0.2582
chr2:24000317-24002742:+	ESCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	5.5934e-04	0.2767
ENSG00000173960.11,UBXN2A	GBM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.4207e-04	0.3067
chr2:24000317-24002742:+	GBM	GSVA_HALLMARK_ADIPOGENESIS	EER	7.6618e-05	0.3325
ENSG00000173960.11,UBXN2A	HNSC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.0635e-03	0.1463
chr2:24000317-24002742:+	KIRC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.6488e-03	0.1924
ENSG00000173960.11,UBXN2A	KIRC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	8.1319e-05	0.2155
chr2:24004352-24004635:+	KIRP	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.2506e-02	-0.2260
ENSG00000173960.11,UBXN2A	KIRP	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.4134e-03	0.2368
chr2:24000317-24002742:+	LAML	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.7101e-02	0.3082
chr2:24000317-24002742:+	LGG	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.3726e-03	0.1540
ENSG00000173960.11,UBXN2A	LGG	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	3.2206e-04	0.1654
ENSG00000173960.11,UBXN2A	LIHC	GSVA_HALLMARK_PEROXISOME	EAG	2.3337e-03	-0.1876
chr2:24000317-24002742:+	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.3547e-03	-0.2238
chr2:24000317-24002742:+	LUAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	6.1611e-04	0.2016
ENSG00000173960.11,UBXN2A	LUAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	2.9968e-05	0.2154
ENSG00000173960.11,UBXN2A	LUSC	GSVA_HALLMARK_PEROXISOME	EAG	1.0035e-03	0.1631
chr2:24000317-24002742:+	LUSC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.5477e-03	0.1715
chr2:24000317-24002742:+	MESO	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.3229e-02	0.3383
chr2:23928024-23928511:+	OV	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.8985e-03	0.4754
chr2:24000317-24002742:+	OV	GSVA_HALLMARK_HEME_METABOLISM	EER	5.3236e-04	0.2243
ENSG00000173960.11,UBXN2A	OV	GSVA_HALLMARK_HEME_METABOLISM	EAG	3.3181e-03	0.1775
ENSG00000173960.11,UBXN2A	PAAD	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	2.6805e-02	0.2131
chr2:24000317-24002742:+	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EER	2.2025e-02	0.2453
chr2:24004352-24004635:+	PAAD	GSVA_HALLMARK_SPERMATOGENESIS	EER	7.9756e-03	-0.5502
ENSG00000173960.11,UBXN2A	PCPG	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.7505e-02	-0.2114
chr2:24000317-24002742:+	PCPG	GSVA_HALLMARK_UV_RESPONSE_DN	EER	7.5146e-03	0.2726
chr2:24004352-24004635:+	PRAD	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EER	4.0404e-03	0.2247
ENSG00000173960.11,UBXN2A	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.4729e-06	0.2343
chr2:24000317-24002742:+	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.2766e-03	0.1608
ENSG00000173960.11,UBXN2A	READ	GSVA_HALLMARK_APICAL_SURFACE	EAG	1.8555e-02	0.2982
chr2:24000317-24002742:+	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	7.3082e-03	0.1993
ENSG00000173960.11,UBXN2A	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.4181e-04	0.2566
chr2:24000317-24002742:+	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.9889e-05	0.2104
ENSG00000173960.11,UBXN2A	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.0179e-02	0.1158
ENSG00000173960.11,UBXN2A	STAD	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.3808e-02	-0.1344
chr2:23928024-23928511:+	STAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	4.9306e-02	0.3972
ENSG00000173960.11,UBXN2A	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.8495e-03	0.2923
chr2:24000317-24002742:+	TGCT	GSVA_HALLMARK_SPERMATOGENESIS	EER	8.5597e-05	0.4063
ENSG00000173960.11,UBXN2A	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.3287e-08	0.2750
chr2:24000317-24002742:+	THCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	8.8699e-03	0.1422
chr2:24004352-24004635:+	THYM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.6806e-04	0.5180
chr2:24000317-24002742:+	UCEC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.0732e-02	0.2582
ENSG00000173960.11,UBXN2A	UCS	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	4.7329e-03	0.3970
chr2:24004352-24004635:+	UCS	GSVA_HALLMARK_DNA_REPAIR	EER	8.6098e-04	0.6239
chr2:24000317-24002742:+	UCS	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.1406e-03	0.5084

Top

7. Enriched editing regions and drugs for UBXN2A

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000173960.11,UBXN2A	ACC	AP.24534	EAG	8.0175e-03	-0.4037
chr2:24004352-24004635:+	BLCA	CI.1040	EER	4.0443e-02	-0.1597
chr2:24000317-24002742:+	BLCA	A.443654	EER	2.0422e-02	-0.1487
ENSG00000173960.11,UBXN2A	BLCA	AZD6482	EAG	1.2897e-02	-0.1404
chr2:24000317-24002742:+	BRCA	EHT.1864	EER	1.4613e-03	0.1089
ENSG00000173960.11,UBXN2A	BRCA	AZD6482	EAG	3.1883e-06	-0.1479
ENSG00000173960.11,UBXN2A	CESC	GDC.0449	EAG	1.6136e-03	0.2000
chr2:24000317-24002742:+	CESC	GDC0941	EER	6.8098e-03	0.1866
ENSG00000173960.11,UBXN2A	CHOL	CI.1040	EAG	2.1263e-02	-0.4991
chr2:24000317-24002742:+	COAD	BIBW2992	EER	3.0099e-02	0.1654
ENSG00000173960.11,UBXN2A	COAD	AZD6482	EAG	1.9629e-03	-0.2176
ENSG00000173960.11,UBXN2A	DLBC	Bosutinib	EAG	4.3452e-02	-0.4155
chr2:24000317-24002742:+	ESCA	Lenalidomide	EER	5.9878e-03	0.2220
ENSG00000173960.11,UBXN2A	ESCA	Imatinib	EAG	3.7767e-02	-0.1654
chr2:24000317-24002742:+	GBM	AG.014699	EER	1.7590e-03	0.2658
ENSG00000173960.11,UBXN2A	GBM	BIRB.0796	EAG	3.1610e-02	0.1762
chr2:24000317-24002742:+	HNSC	FH535	EER	1.4772e-02	0.1263
ENSG00000173960.11,UBXN2A	HNSC	Cyclopamine	EAG	1.0027e-03	0.1625
ENSG00000173960.11,UBXN2A	KICH	ABT.263	EAG	2.0578e-02	0.3899
chr2:24000317-24002742:+	KIRC	Lapatinib	EER	2.2739e-02	-0.1402
ENSG00000173960.11,UBXN2A	KIRC	BMS.536924	EAG	1.9183e-03	0.1707
ENSG00000173960.11,UBXN2A	KIRP	GW.441756	EAG	8.8881e-04	-0.2463
chr2:24000317-24002742:+	KIRP	GDC0941	EER	1.2435e-02	0.2178
chr2:24004352-24004635:+	KIRP	AUY922	EER	3.7474e-06	0.4883
ENSG00000173960.11,UBXN2A	LAML	BI.2536	EAG	1.1336e-02	0.2909
chr2:24000317-24002742:+	LGG	Axitinib	EER	1.0017e-05	0.2114
ENSG00000173960.11,UBXN2A	LGG	AZD8055	EAG	9.2443e-06	0.2032
chr2:24000317-24002742:+	LIHC	BX.795	EER	3.3842e-05	0.3123
ENSG00000173960.11,UBXN2A	LIHC	AICAR	EAG	1.0410e-04	0.2379
chr2:24000317-24002742:+	LUAD	Methotrexate	EER	2.4663e-02	0.1333
ENSG00000173960.11,UBXN2A	LUAD	Embelin	EAG	3.6624e-02	-0.1088
ENSG00000173960.11,UBXN2A	LUSC	AG.014699	EAG	4.0400e-02	-0.1020
chr2:24000317-24002742:+	LUSC	Epothilone.B	EER	1.6856e-03	-0.1702
chr2:24000317-24002742:+	MESO	AMG.706	EER	3.1029e-02	-0.2966
chr2:24004352-24004635:+	MESO	AG.014699	EER	2.5444e-04	0.5095
chr2:23928024-23928511:+	OV	DMOG	EER	1.3237e-03	-0.5212
ENSG00000173960.11,UBXN2A	OV	CGP.082996	EAG	6.0807e-03	-0.1660
chr2:24000317-24002742:+	OV	CGP.082996	EER	1.2546e-03	-0.2092
chr2:24000317-24002742:+	PAAD	CEP.701	EER	2.6302e-03	-0.3204
chr2:24004352-24004635:+	PAAD	Axitinib	EER	1.7079e-02	0.5028
ENSG00000173960.11,UBXN2A	PAAD	CEP.701	EAG	7.9093e-03	-0.2555
ENSG00000173960.11,UBXN2A	PCPG	Camptothecin	EAG	4.3199e-03	0.2526
chr2:24000317-24002742:+	PCPG	AZD.2281	EER	1.7209e-02	0.2439
ENSG00000173960.11,UBXN2A	PRAD	Embelin	EAG	3.1625e-04	-0.1828
chr2:24000317-24002742:+	PRAD	AUY922	EER	7.4539e-03	-0.1507
chr2:24004352-24004635:+	PRAD	GNF.2	EER	1.9509e-04	-0.2904
ENSG00000173960.11,UBXN2A	READ	Metformin	EAG	2.4795e-02	0.2849
chr2:24000317-24002742:+	SARC	AZD.2281	EER	1.9561e-03	0.2293
ENSG00000173960.11,UBXN2A	SARC	GDC.0449	EAG	4.7582e-03	0.1918
ENSG00000173960.11,UBXN2A	SKCM	CGP.082996	EAG	1.6763e-02	-0.1192
chr2:24000317-24002742:+	SKCM	ABT.888	EER	8.7058e-04	-0.1733
chr2:24000317-24002742:+	STAD	AZD8055	EER	1.5645e-02	0.1374
chr2:23928024-23928511:+	STAD	BMS.509744	EER	8.7982e-03	-0.5126
ENSG00000173960.11,UBXN2A	STAD	BMS.536924	EAG	2.7501e-02	-0.1204
ENSG00000173960.11,UBXN2A	TGCT	BMS.536924	EAG	1.8911e-04	0.3472
chr2:24000317-24002742:+	TGCT	BMS.536924	EER	3.4079e-04	0.3733
chr2:24000317-24002742:+	THCA	AZ628	EER	3.0343e-03	0.1608
ENSG00000173960.11,UBXN2A	THCA	AZD6482	EAG	1.0951e-07	-0.2577
chr2:24004352-24004635:+	THYM	CGP.60474	EER	2.6233e-02	-0.3313
chr2:24000317-24002742:+	THYM	AZD.2281	EER	6.3116e-03	0.3379
ENSG00000173960.11,UBXN2A	THYM	KIN001.135	EAG	9.7095e-03	-0.2823
ENSG00000173960.11,UBXN2A	UCEC	BI.D1870	EAG	1.1275e-02	0.2366
chr2:24000317-24002742:+	UCEC	Doxorubicin	EER	3.1316e-03	0.3264
ENSG00000173960.11,UBXN2A	UCS	Docetaxel	EAG	1.4084e-02	-0.3486
chr2:24004352-24004635:+	UCS	GW843682X	EER	1.3990e-03	-0.6036
chr2:24000317-24002742:+	UCS	KIN001.135	EER	1.1209e-03	-0.5348
ENSG00000173960.11,UBXN2A	UVM	Axitinib	EAG	2.1154e-02	-0.3680

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType